The sentiment on the biotech sector remains absolutely dismal here at the start of 2022. The SPDR S&P Biotech ETF (XBI) is off almost 20% in 2021 after a lousy last three quarters of 2021. Outside of the financial crisis over a decade ago, I can't remember a time when this sector seemed so oversoldSmall-caps aren't getting much love either as th...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.